FOTEMUSTINE IN PATIENTS WITH ADVANCED GASTRIC-CANCER, A PHASE-II TRIAL FROM THE EORTC-GITCCG (EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER, GASTROINTESTINAL-TRACT CANCER COOPERATIVE GROUP)

Authors
ROUGIER P VANPOTTELSBERGHE C KOK T PAILLOT B WAGENER T DEGREVE J FABRI MC GERARD B VANGLABBEKE M BLEIBERG H
Citation
P. Rougier et al., FOTEMUSTINE IN PATIENTS WITH ADVANCED GASTRIC-CANCER, A PHASE-II TRIAL FROM THE EORTC-GITCCG (EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER, GASTROINTESTINAL-TRACT CANCER COOPERATIVE GROUP), European journal of cancer, 32A(8), 1996, pp. 1432-1433
Citations number
9
Categorie Soggetti
Oncology
Journal title
European journal of cancer → ACNP
ISSN journal
09598049
Volume
32A
Issue
8
Year of publication
1996
Pages
1432 - 1433
Database
ISI
SICI code
0959-8049(1996)32A:8<1432:FIPWAG>2.0.ZU;2-F
Abstract
Fotemustine activity was evaluated in 26 patients, mostly pretreated, with advanced gastric cancer. Its main toxicity was haematological wit h grade 3-4 neutropenia in 32% and grade 3-4 thrombocytopenia in 50% o f the patients, complicated by 2 toxicity-related deaths due to haemor rhage. No complete or partial responses were observed in the 26 eligib le patients and median survival was only 11 weeks. Fotemustine therefo re has no activity in advanced gastric cancer. Copyright (C) 1996 Else vier Science Ltd